Mouse anti-Tumor Necrosis Factor Receptor, clone H398 (Monoclonal)
| Product Name | Mouse anti-Tumor Necrosis Factor Receptor, clone H398 (Monoclonal) |
|---|---|
| Description | Mouse anti-Tumor Necrosis Factor Receptor, clone H398 (Monoclonal) |
| Host | Mouse |
| Clonality | Monoclonal |
| Clone | H398 |
| Immunogen | Unknown or proprietery to MONOSAN and/or its suppliers |
| Isotype | IgG2a |
| Reactivity | Human, Rat |
| Applications | IHC-Fr, ELISA, FA, FC, IP, WB |
| Working Dilutions | ,,,,, |
| Diluent Buffer | PBS with 0.1% BSA and 0.02% sodium azide |
| Concentration | 100 ug/ ml |
| Storage | 2-8°C |
| Notes | The monoclonal antibody H398 recognizes the extracellular part of the Tumor Necrosis Factor Receptor type I (TNF-RI) of the membrane-bound as well as the soluble receptor. TNF-RI (~55-60 kDa) is present on most cell types and is considered to play a prominent role in cell stimulation by TNF-alpha. TNF-alpha activates inflammatory responses, induces apoptosis, regulates cellular proliferation, and may even promote cancer progression. The effects of TNF-alpha are mediated by TNF-RI and TNF-RII, which have both distinct and overlapping downstream signaling cascades. Induction of cytotoxicity and other functions are mediated largely via TNF-RI. TNF-RI is equally well activated by both the 17 kDa soluble and 26 kDa membrane-bound form, whereas TNF-RII is efficiently activated only by the membrane bound form of TNF-alpha. TNF-RI signaling is initiated when trimeric TNF-alpha binds TNF-RI receptors. Subsequent TNF-RI trimerization promotes the recruitment of a proximal signaling complex composed of TNF Receptor Associated protein with a Death Domain (TRADD), Receptor Interacting Protein (RIP), cellular Inhibitor of Apoptosis Protein 1 (cIAP1), TNF Receptor Associated Factor 2 (TRAF2), and likely TRAF5. Studies with TNF-RI-deficient mice indicate that TNF-RI mediates most of the proliferation, pro-inflammatory, and apoptosis-activating pathways. |
| References | Thoma; B et al. J Exp Med 1990; 172: 1019. Grell, M et al Lymphokine Cytokine Res 1993, 12: 143. Scheurich; P et al. Tumor Necrosis factor 1993; 4: 52. Grell M et al. Proc Natl Acad Sci USA 1998; 95: 570. Krippner-Heidenreich A et al. J Immunol 2008; 180: 8176 |
| Supplier | MONOSAN |
All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.
